Filing Flows › Entrada Therapeutics (TRDA) › Q3 2025
Entrada Therapeutics (TRDA) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 6, 2025
Entrada Therapeutics (TRDA) reported revenue of $1.6M for the third quarter 2025 (Q3 2025), -92% from a year earlier and -17% from the quarter before.
Entrada Therapeutics, Q3 2025: revenue $1.6M (-92% year over year), net loss $44.1M, operating cash flow −$28.3M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.6M | -17% | -92% |
| Operating profit | −$47.1M | — | — |
| Net earnings | −$44.1M | — | — |
| Operating cash flow | −$28.3M | — | — |
What changed
Revenue was $1.6M in Q3 2025, down 92% year over year and down 17% from the previous quarter.
Operating costs exceeded revenue by $47.1M, an operating margin of -2915.2%. Total costs grew 18% against a revenue fall of 92%. The fastest-growing cost line was Research & development (+23%). The quarter ended with a net loss of $44.1M, wider than the previous quarter's $43.1M loss.
Operating cash flow was −$28.3M. Non-cash charges added back $1.2M of depreciation and $5.1M of share-based compensation. Working capital and other items added $9.5M. Capital expenditures of −$171K exceeded it, leaving free cash flow of −$28.1M.
Questions
What was Entrada Therapeutics' revenue in the third quarter 2025?
Entrada Therapeutics (TRDA) reported revenue of $1.6M for the third quarter 2025 (Q3 2025), -92% from a year earlier and -17% from the quarter before.